|
|
|
|
|
|
|
|
|
|
Neoadjuvant chemotherapy for advanced-stage ovarian cancer: Are the ASCO and SGO recommendations warranted?
Highlights
- •
- The guidelines endorse neoadjuvant chemotherapy for potentially resectable disease.
- •
- Women with no residual disease after primary surgery have the best survival rates.
- •
- All women with potentially resectable disease should strive for this outcome.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.